Cambium Bio Raises Trial Funds as AdAlta Wins Cell-Therapy Validation

• AdAlta rose 16.67% after manufacturing partner Oribiotech signed a 10-year deal worth up to US$120 million.
• Vectus fell 10.00% despite a FY2026 profit, as most of the result came from a transaction involving XORTX shares and warrants.
• Cambium Bio secured firm commitments for a proposed A$7.1 million placement to fund its Elate Ocular Phase 3 programme.
• Proteomics International began selling two Promarker tests through Healius, but wider sales are not expected until Q2 FY27.
• EBR Systems moved closer to a decision on its new US manufacturing facility, while Epiminder reached 75 patients in its epilepsy study.

The biggest weekly moves

AdAlta (ASX:1AD) was the strongest mover, rising 16.67%. Its manufacturing partner, Oribiotech, signed a 10-year agreement worth up to US$120 million with an unnamed commercial-stage drug company. The deal does not give AdAlta direct revenue. Investors still welcomed the proof that Oribiotech’s automated cell-therapy system can win a major customer.

Vectus Biosystems (ASX:VBS) dropped 10.00%. The company reported a FY2026 profit of $1.56 million, but a $2.55 million gain from selling its VB4-P5 compound to XORTX drove much of that result. Vectus had $718,594 in cash after spending $573,395 on operations. Its auditor also warned that the company may not have enough funding to continue without further support.

Patrys (ASX:PAB) gained 9.68% after appointing an international clinical advisory committee. The group will help plan studies for RLS-2202, an injectable quetiapine treatment being tested for delirium in hospital patients. The move adds experience to the programme, but it does not provide proof that the treatment works.

Biotech companies prepare for bigger trials

Cambium Bio (ASX:CMB) rose 8.70% after securing firm commitments for a A$7.1 million share placement. The proposed funding package would reach A$10.85 million. The money is intended for the pivotal Phase 3 Elate Ocular study. Phase 3 is the large patient study usually needed before a company seeks broad approval. Shareholders must approve three linked resolutions by 30 November 2026.

Entropy Neurodynamics (ASX:ENP) added 5.00% after all six patients in the first group of its binge-eating trial kept a meaningful improvement for 12 weeks. Three patients reported no binge-eating episodes during the follow-up. The study was small, open to everyone and had no comparison group. That makes the result encouraging, but not conclusive. Data from the next group is due in the fourth quarter of 2026.

Prescient Therapeutics (ASX:PTX) was unchanged after extending its share purchase plan by three days. Eligible investors can buy shares at $0.065, an 18.8% discount to the recent average price. The company plans to release the offer result on 24 September, before a briefing on its PTX-100 programme.

Devices move through testing and approval

EBR Systems (ASX:EBR) rose 1.96% after the US regulator began inspecting its new Santa Clara manufacturing facility. The inspection checks whether the site can produce the company’s wireless heart-pacing system to the required standard. EBR still expects approval by the end of 2026. It also plans to file a labelling update that gives greater prominence to risks linked to ultrasound-guided pacing.

EMVision (ASX:EMV) fell 2.01% despite completing a 10-patient roadside stroke-scanner study. The device took an average of 6.7 minutes to scan and caused no reported device-related harm. The study tested ease of use, not whether the scanner can diagnose stroke. A larger study using newer units is now the important next step.

Epiminder (ASX:EPI) declined 3.33% after enrolling the 75th patient in its US epilepsy study. Recruitment remains on schedule, with 100 patients expected in November and all 210 patients targeted by the first half of calendar 2027. The update gave no results on whether the device works or is safe.

Diagnostics seek paying customers

Proteomics International (ASX:PIQ) fell 7.14% as it began a controlled release of two Promarker tests through Healius. The tests cost $495 and $997 for private-paying patients. Healius provides access to about 1,900 collection centres, but national sales are not expected until Q2 FY27. Investors still lack evidence of customer numbers and recurring revenue.

Pacific Edge (ASX:PEB) rose 7.32% after raising NZ$36.1 million. The company is relying on a possible US Medicare coverage decision and a proposed US$1,328 price for its Cxbladder Triage test. Revenue fell 44.8% to NZ$13.6 million in FY26, while the net loss widened to NZ$35.8 million. The company says it needs about 55,000 tests a year to reach profit.

Emyria (ASX:EMD) gained 4.17% after presenting its Australian psychedelic-treatment model at a US FDA public hearing. The company discussed staff training, patient safety and record keeping. It has not announced US approval, a commercial agreement or a payment from the regulator.

Capital moves and corporate deals

Paragon Care (ASX:PGC) rose 7.69% after proposing a buy-back of up to 82.8 million shares. At the latest closing price, the maximum cost would be about $10.76 million. An employee trust may also buy up to 23.9 million shares. The buy-back could support the share price if completed, but the company has not promised to purchase the full amount.

Freedom Care Group (ASX:FCG) was unchanged after its 29%-owned Koala Disability Care agreed to sell a Tuggerah disability-care business for $2.238 million plus GST. Twenty per cent of the price depends on client-transition adjustments. The sale could send cash to Freedom Care, but the amount and timing remain unknown.

AdAlta’s rise and Paragon Care’s gain continued after their key announcements, while Vectus’s earlier price gap left the stock lower despite an 8.00% move since reopening. In plain terms, Vectus recovered part of the drop, but buyers did not erase the week’s loss. Proteomics International also faced a different test: proving that a controlled product launch can become regular patient demand.

Bottom Line?

The next week should bring clearer evidence from Cambium Bio’s shareholder process, Proteomics International’s early test sales and EBR Systems’ facility inspection. Investors will also watch Prescient’s share plan result on 24 September, while Entropy Neurodynamics is expected to provide its next trial data in the fourth quarter of 2026.

Questions in the middle?

• Will Cambium Bio shareholders approve the linked resolutions needed to complete the A$10.85 million funding package by 30 November 2026?
• How many patients will pay for Proteomics International’s Promarker tests before national sales begin in Q2 FY27?
• Can Vectus Biosystems fund the Phase 1 trial of VB0004 after its auditor raised concerns about the company’s ability to continue?